Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.
Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.
Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.
Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.
MediWound Ltd. (Nasdaq: MDWD) announced positive initial results from its Phase I/II study of MW005 for low-risk Basal Cell Carcinoma (BCC). The data indicates that MW005 is safe, well-tolerated, and effective, with most patients achieving complete histological clearance of target lesions after treatment. The study involved eleven patients receiving seven topical applications over eight weeks. CEO Ofer Gonen highlighted the significant market potential for non-surgical BCC treatments. Final data is expected in the second half of 2022, further validating MW005's clinical efficacy.
MediWound Ltd. (Nasdaq: MDWD) announced an upcoming oral presentation at the Advanced Wound Care Summit on July 13-14, 2022, in Boston, MA. Dr. Robert Snyder will present an analysis titled “Market Landscape Analysis & EscharEx Market Potential” at 3:00 pm ET on July 13. The presentation will cover the wound care market and the potential of EscharEx, a therapy for chronic wound debridement currently in advanced clinical development. EscharEx has shown safety and efficacy in Phase 2 trials, and a meeting with the FDA is targeted for the second half of 2022.
MediWound Ltd. (Nasdaq: MDWD) announced positive results from a Phase 2 study of EscharEx, a biotherapeutic solution for debridement in venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). The study found that 70% of patients achieved complete debridement within up to 8 applications, with an average of 3.9 applications required. A significant reduction of 35% in wound size and effective biofilm disruption were noted. EscharEx was well-tolerated with ongoing biomarker analysis, underscoring its potential as a non-surgical treatment option.
MediWound Ltd. (Nasdaq: MDWD) will host an in-person Key Opinion Leader (KOL) breakfast meeting on EscharEx on July 12, 2022, at the St. Regis Hotel, New York City. Starting at 8:00 AM ET, the event will feature presentations from leading experts discussing wound debridement practices and EscharEx's clinical study results. CEO Ofer Gonen will provide a company update, followed by a Q&A session. The event will be webcast for those unable to attend in person. EscharEx is aimed at treating chronic wounds, showcasing MediWound's commitment to innovative wound care solutions.
MediWound Ltd. (Nasdaq: MDWD) has appointed Tzvi Palash as Chief Operating Officer (COO), effective June 30, 2022. Palash brings over 35 years of operational experience from prominent pharmaceutical companies. His previous roles include COO at Enlivex and Gamida Cell, where he oversaw critical BLA submissions. His expertise will support MediWound's development of EscharEx and the resubmission of the NexoBrid BLA. NexoBrid is a bromelain-based product for burn care marketed in the EU and at the registration stage in the U.S., backed by BARDA.
MediWound Ltd. (Nasdaq: MDWD) has appointed Ofer Gonen as its new Chief Executive Officer, effective June 30, 2022, succeeding Sharon Malka, who will transition to the Board of Directors. Gonen brings over 20 years of experience in life sciences and business development, previously serving as CEO of Clal Biotechnology Industries, MediWound's largest shareholder. The leadership change aims to position the company for long-term growth and enhance its capabilities in treating burns and wound care.
MediWound Ltd. (NASDAQ: MDWD) announced its Q1 2022 financial results, reporting revenues of $4.4 million, a 24% decline from $5.8 million in Q1 2021. The company faced a 56% drop in product revenue, primarily due to decreased emergency stockpile procurement by BARDA. Despite a net loss of $3.6 million or $0.12 per share, MediWound highlighted the positive results from its U.S. Phase 2 trial of EscharEx®, achieving primary and secondary endpoints with no safety issues. The company has raised $10 million through equity offerings and is on track for NexoBrid BLA resubmission by mid-year.
MediWound Ltd. (Nasdaq: MDWD) has announced positive results from its U.S. Phase 2 clinical study of EscharEx® for treating venous leg ulcers (VLUs). The study met its primary and key secondary endpoints with statistically significant improvements, including a 63% complete debridement rate in 14 days versus 30% for the control. EscharEx demonstrated a median time to complete debridement of 9 days compared to 59 days for standard care. The FDA meeting is anticipated in the second half of 2022 to discuss advancing to Phase 3 trials. No safety issues were observed, reinforcing EscharEx's therapeutic potential.
MediWound Ltd. (Nasdaq: MDWD) will announce its first-quarter financial results on May 17, 2022. The release will be followed by a conference call at 8:30 AM ET for management to discuss these results and provide corporate updates. MediWound specializes in bio-therapeutic solutions for tissue repair, notably its product NexoBrid for thermal burns, which has received support from BARDA. The company is also developing EscharEx for chronic wounds and MW005 for non-melanoma skin cancers. The webcast will be accessible for 90 days following the call.
MediWound Ltd. (Nasdaq: MDWD) announced that its EscharEx® phase 2 clinical study results were featured at the SAWC Spring Conference. The poster highlighting the pharmacology study was among ten selected from 235 presented. The data indicated EscharEx effectively debrided wounds and reduced biofilm while being safe for patients with diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). CEO Sharon Malka expressed optimism about EscharEx's potential in the over billion-dollar wound care market, emphasizing the urgent need for new debridement solutions.
FAQ
What is the current stock price of Mediwound (MDWD)?
What is the market cap of Mediwound (MDWD)?
